Advanced in Calcium Pyrophosphate Arthritis

Dr. Jeffrey S. Carlin

Rheumatology
The Association Of University Physicians
1959 Ne Pacific St, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
Advanced in Calcium Pyrophosphate Arthritis
The Association Of University Physicians
1959 Ne Pacific St, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeffrey Carlin is a Rheumatologist in Seattle, Washington. Dr. Carlin is rated as an Advanced provider by MediFind in the treatment of Calcium Pyrophosphate Arthritis. His top areas of expertise are Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA), Scleroma, and Scleroderma. Dr. Carlin is currently accepting new patients.

His clinical research consists of co-authoring 8 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in WA
Hospital Affiliations
University Of Washington Medical Ctr
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
PacificSource
  • PPO
Premera
  • EPO
  • PPO

Locations

THE ASSOCIATION OF UNIVERSITY PHYSICIANS
1959 Ne Pacific St, Seattle, WA 98195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drug: Ifetroban
Study Phase: Phase 2
Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis
Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: June 12, 2025
Intervention Type: Drug
Study Drug: Hydroxychloroquine
Study Phase: Phase 2
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Iloprost
Study Phase: Phase 3
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: August 30, 2023
Intervention Type: Drug
Study Drug: Belumosudil (KD025)
Study Phase: Phase 2
A Phase 2, Open-label Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Phase 2, Open-label Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Enrollment Status: Terminated
Publish Date: June 05, 2023
Intervention Type: Drug
Study Drug: Belumosudil
Study Phase: Phase 2
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 7 Less Clinical Trials

8 Total Publications

T Cells Promote Distinct Transcriptional Programs of Cutaneous Inflammatory Disease in Keratinocytes and Dermal Fibroblasts.
T Cells Promote Distinct Transcriptional Programs of Cutaneous Inflammatory Disease in Keratinocytes and Dermal Fibroblasts.
Journal: The Journal of investigative dermatology
Published: August 30, 2024
Similar Doctors
Distinguished in Calcium Pyrophosphate Arthritis
Dr. Caner Sakin
Rheumatology
Distinguished in Calcium Pyrophosphate Arthritis
Dr. Caner Sakin
Rheumatology

Valley Medical Group-Renton

400 S 43rd St, 
Renton, WA 
 (14.9 miles away)
425-228-3450
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Caner Sakin is a Rheumatologist in Renton, Washington. Dr. Sakin is rated as a Distinguished provider by MediFind in the treatment of Calcium Pyrophosphate Arthritis. His top areas of expertise are Rheumatoid Arthritis (RA), Calcium Pyrophosphate Arthritis, Lupus Nephritis, and Polymyalgia Rheumatica. Dr. Sakin is currently accepting new patients.

Distinguished in Calcium Pyrophosphate Arthritis
Dr. Pedro E. Trujillo
Rheumatology
Distinguished in Calcium Pyrophosphate Arthritis
Dr. Pedro E. Trujillo
Rheumatology
4033 Talbot Rd S, Ste 570, 
Renton, WA 
 (14.8 miles away)
425-656-5400
Languages Spoken:
English
See accepted insurances

Pedro Trujillo is a Rheumatologist in Renton, Washington. Dr. Trujillo is rated as a Distinguished provider by MediFind in the treatment of Calcium Pyrophosphate Arthritis. His top areas of expertise are Chondrocalcinosis 2, Calcium Pyrophosphate Arthritis, Psoriatic Arthritis, and Polymyalgia Rheumatica.

Advanced in Calcium Pyrophosphate Arthritis
Dr. Daniel J. Kim
Rheumatology | Palliative Medicine
Advanced in Calcium Pyrophosphate Arthritis
Dr. Daniel J. Kim
Rheumatology | Palliative Medicine
11417 124th Ave Ne, Suite 103, 
Kirkland, WA 
 (7.1 miles away)
425-899-1664
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Kim is a Rheumatologist and a Palliative Medicine provider in Kirkland, Washington. Dr. Kim has been practicing medicine for over 16 years and is rated as an Advanced provider by MediFind in the treatment of Calcium Pyrophosphate Arthritis. His top areas of expertise are Rheumatoid Arthritis (RA), Fibromyalgia, Rheumatoid Vasculitis, and Ankylosing Spondylitis. Dr. Kim is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Carlin's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 18 Advanced Conditions
    View All 38 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile